NHK has learned that a third-party committee of experts has found no safety problems so far with a procedure to repair spinal cord injuries by transplanting cells derived from induced pluripotent stem cells, or iPS cells.
A team led by Okano Hideyuki and Nakamura Masaya, both professors at Keio University, performed the world's first procedure in December.
They transplanted iPS-derived nerve cells into a patient whose spinal cord had been damaged.
The team submitted data on the patient to the Independent Data Monitoring Committee.
The committee concluded on Tuesday that the patient has so far not shown any grave side effects, and gave the go-ahead for a second clinical trial.
The committee did not assess the medical effect of the transplant, as it plans to monitor this aspect over the course of one year.
The team plans to transplant iPS-derived cells into four patients. They will start accepting applications next month for their second clinical trial.
A team led by Okano Hideyuki and Nakamura Masaya, both professors at Keio University, performed the world's first procedure in December.
They transplanted iPS-derived nerve cells into a patient whose spinal cord had been damaged.
The team submitted data on the patient to the Independent Data Monitoring Committee.
The committee concluded on Tuesday that the patient has so far not shown any grave side effects, and gave the go-ahead for a second clinical trial.
The committee did not assess the medical effect of the transplant, as it plans to monitor this aspect over the course of one year.
The team plans to transplant iPS-derived cells into four patients. They will start accepting applications next month for their second clinical trial.
Similar Readings (5 items)
Team: iPS-derived cornea transplant proved safe, effective
Japan team says stem cell treatment helped improve spinal cord injuries
iPS-derived heart cell transplant conducted at university in southwest Japan
Researchers announce first iPS cell transplant for cornea disease
Clinical trials underway for type one diabetes using iPS cells
Summary
Third-party committee approves second clinical trial of iPS cell transplant procedure to repair spinal cord injuries, led by Hideyuki Okano and Masaya Nakamura at Keio University. No grave side effects detected thus far. First procedure performed in December 20XX, transplanted iPS-derived nerve
Statistics
156
Words1
Read CountDetails
ID: 62443641-6d9c-459c-872e-5f93c0a80b98
Category ID: nhk
URL: https://www3.nhk.or.jp/nhkworld/en/news/20220330_25/
Date: March 30, 2022
Created: 2022/03/30 19:51
Updated: 2025/12/09 17:21
Last Read: 2022/03/30 19:51